Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 9, 2013, Pages 2007-2011

  Staud, Frantisek ^a   Cerveny, Lukas ^a   Ahmadimoghaddam, Davoud ^a   Ceckova, Martina ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Drug drug interactions; Efflux transporter; Multidrug and toxin extrusion; Pharmacokinetics

Indexed keywords

ACICLOVIR; CAPTOPRIL; CEFALEXIN; CEFRADINE; CETIRIZINE; CIMETIDINE; CISPLATIN; DILTIAZEM; FAMOTIDINE; FEXOFENADINE; GANCICLOVIR; IMATINIB; INDINAVIR; LEVOFLOXACIN; MESNA; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2K; MULTIDRUG AND TOXIN EXTRUSION PROTEIN1; ORGANIC CATION TRANSPORTER; OXALIPLATIN; PROCAINAMIDE; PROTEIN; QUINIDINE; QUININE; RITONAVIR; SLC47A1 PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BODY DISTRIBUTION; DRUG EXCRETION; DRUG INTERACTION; DRUG RESISTANCE; DRUG TOXICITY; DRUG TRANSPORT; GENE EXPRESSION; GENE STRUCTURE; GENETIC POLYMORPHISM; MAMMAL; PHARMACOKINETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TOXICOKINETICS; URINARY EXCRETION;

MAMMALIA;

DRUG-DRUG INTERACTIONS; EFFLUX TRANSPORTER; MULTIDRUG AND TOXIN EXTRUSION; PHARMACOKINETICS;

ANIMALS; DRUG INTERACTIONS; HUMANS; KIDNEY; LIVER; ORGANIC CATION TRANSPORT PROTEINS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 84885114750     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.06.022     Document Type: Short Survey

References (33)

1. Ahmadimoghaddam D, Hofman J, Zemankova L., Nachtigal P, Dolezelova E, Cerveny L., et al Synchronized activity of organic cation transporter 3 (Oct3/Slc22a3)and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPP+ in rat. Toxicological Sciences 2012; 128:471-81.
2. Ahmadimoghaddam D, Staud F. Transfer of metformin across the rat placenta is mediated by organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) protein. Reproductive Toxicology 2013; 39:17-22.
3. Ahmadimoghaddam D, Zemankova L, Nachtigal P., Dolezelova E, Neumanova Z, Cer-veny L, et al Organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter in the placenta and fetal tissues: expression profile and fetus protective role at different stages ofgestation. Biology of Reproduction 2013; 88:55.
4. Aleksunes LM, Cui Y, Klaassen CD Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2008; 36:1960-70.
5. Astorga B, Ekins S, Morales M., Wright SH Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. Journal of Pharmacology and Experimental Therapeutics 2012; 341:743-55.
6. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009; 58:745-9.
7. Damme K, Nies AT, Schaeffeler E, Schwab M. Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. Drug Metabolism Reviews 2011; 43:499-523.
8. Gaowa A, Motohashi H, Katsura T, Inui K. Effects of metabolic acidosis on expression levels of renal drug transporters. Pharmaceutical Research 2011; 28:1023-30.
9. Graham GG, Punt J, Arora M., Day RO, Doogue MP, Duong JK, et al Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics 2011; 50:81-98.
10. Grottker J, Rosenberger A, Burckhardt G, Hagos Y. Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents. Drug Metabolism and Drug Interactions 2011; 26:181-9.
11. Grun B, Kiessling MK, Burhenne J, Riedel KD, Weiss J, Rauch G, et al. Trimethoprimmetformin interaction and its genetic modulation by OCT2 and MATE1. British Journal of Clinical Pharmacology 2013, doi:10.1111/bcp.12079 [Epub ahead of print].
12. Ha Choi J., Wah Yee S, Kim MJ, Nguyen L, Ho Lee J, Kang JO, et al Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenetics and Genomics 2009; 19:770-80.
13. Choi JH, Yee SW, Ramirez A.H., Morrissey KM, Jang GH, Joski PJ, et al A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clinical Pharmacology and Therapeutics 2011; 90:674-84.
14. Ito S, Kusuhara H, Kumagai Y., Moriyama Y, Inoue K, Kondo T., et al N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clinical Pharmacology and Therapeutics 2012a; 92:635-41.
15. Ito S, Kusuhara H, Yokochi M., Toyoshima J, Inoue K, Yuasa H, et al. ompetitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. Journal of Pharmacology and Experimental Therapeutics 2012b; 340:393-403.
16. Kajiwara M, Terada T, Asaka J., Ogasawara K, Katsura T, Ogawa O., et al Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1. American Journal of Physiology Renal Physiology 2007; 293:F1564-70. (Pubitemid 350085992)
17. Komatsu T, Hiasa M, Miyaji T., Kanamoto T, Matsumoto T, Otsuka M., et al Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter. International Journal of Biochemistry and Cell Biology 2011; 43:913-8.
18. Kusuhara H, Ito S, Kumagai Y., Jiang M, Shiroshita T, Moriyama Y., et al Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clinical Pharmacology and Therapeutics 2011; 89:837-44.
19. Lu H, Gonzalez FJ, Klaassen C. Alterations in hepatic mRNA expression of phase II enzymes and xenobiotic transporters after targeted disruption of hepatocyte nuclear factor 4 alpha. Toxicological Sciences 2010; 118:380-90.
20. Minematsu T, Giacomini KM Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Molecular Cancer Therapeutics 2011; 10:531-9.
21. Morita Y, Kodama K, Shiota S., Mine T, Kataoka A, Mizushima T., et al NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrobial Agents and Chemotherapy 1998; 42: 1778-82. (Pubitemid 28311578)
22. Nishihara K, Masuda S, Ji L., Katsura T, Inui K. Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochemical Pharmacology 2007; 73:1482-90. (Pubitemid 46452587)
23. Otsuka M, Matsumoto T, Morimoto R., Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proceedings of the National Academy of Sciences of the United States of America 2005; 102:17923-8. (Pubitemid 41798478)
24. Sato T, Masuda S, Yonezawa A., Tanihara Y, Katsura T, Inui K. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochemical Pharmacology 2008; 76:894-903.
25. Stocker SL, Morrissey KM, Yee S.W., Castro RA, Xu L, Dahlin A, et al The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clinical Pharmacology and Therapeutics 2013; 93:186-94.
26. Tkac I, Klimcakova L, Javorsky M., Fabianova M, Schroner Z, Hermanova H, et al. Phar-macogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes, Obesity and Metabolism 2012; 15:189-91.
27. Toyama K, Yonezawa A, Masuda S., Osawa R, Hosokawa M, Fujimoto S., et al Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. British Journal of Pharmacology 2012; 166: 1183-91.
28. Tsuda M, Terada T, Mizuno T., Katsura T, Shimakura J, Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Molecular Pharmacology 2009; 75:1280-6.
29. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clinical Pharmacology and Therapeutics 2009; 86:299-306.
30. Wittwer MB, Zur AA, Khuri N, Kido Y., Kosaka A, Zhang X, et al Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. Journal of Medicinal Chemistry 2013; 56:781-95.
31. Yokoo S, Yonezawa A, Masuda S., Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochemical Pharmacology 2007; 74:477-87. (Pubitemid 46963232)
32. Yonezawa A, Inui K. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharma-cogenomics. BritishJournal of Pharmacology 2011; 164:1817-25.
33. Zhang X, He X, Baker J., Tama F, Chang G, Wright SH Twelve transmembrane helices form the functional core of mammalian MATE1 (multidrug and toxin extruder 1) protein. Journal of Biological Chemistry 2012; 287:27971-82.